Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Less-Invasive Repair of the Mitral Valve

By HospiMedica staff writers
Posted on 20 Dec 2006
A new method of treating mitral regurgitation (MR) provides a less-invasive alternative to open-heart surgery.

A new percutaneous mitral valve repair system called E-valve involves suturing the free edge of the anterior leaflet of the mitral valve to a corresponding portion on the posterior leaflet, creating a point of permanent coaptation: the joining together or fitting of two surfaces. More...
This creates a functional double orifice during diastole. The valve continues to open on both sides of the suture, allowing ample blood flow through the valve from the left atrium to left ventricle, while assuring proper leaflet coaptation and effective valve closure when blood is pumped from the left ventricle to the rest of the body. This edge-to-edge (E2E) technique is performed with or without adjunctive annuloplasty.

A steerable guide catheter is inserted into the femoral vein at the groin and provides a conduit to access the mitral valve. The implantable clip, called MitraClip, is delivered to the site with a proprietary clip delivery system, and is then used to grasp and join the leaflets of the mitral valve. If necessary, a second clip may be placed. The principal benefit of the system is that it enables the clinician to repair the mitral valve while the heart is beating, without cardiopulmonary bypass (CPB) and without the need for a thoracotomy or sternotomy. If the physician is not satisfied with initial clip placement, the system is designed to allow for repositioning or removal of the MitraClip. This safety feature is intended to preserve the patient's conventional surgical options and outlook.

The Mitraclip is being developed by Evalve (Menlo Park, CA, USA). Clinical trial data of phase II of a study called EVEREST (endovascular valve edge-to-edge repair study), involving the first 92 non-randomized patients with completed 30-day follow-up and echocardiographic core lab analysis, were presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2006 annual meeting, held in Washington (D.C., USA) in October 2006.

"The MitraClip offers patients a less invasive option with faster recovery and could create a paradigm shift in MR treatment. We are encouraged by the results to date, which show we are able to achieve and, more importantly, maintain a clinically meaningful reduction in MR in a majority of patients undergoing the procedure,” said Dr. Ted Feldman, a professor of medicine and director of the cardiac catheterization laboratory at Evanston Northwestern Hospital (IL, USA) and co-principal investigator of the EVEREST trial.



Related Links:
Evalve
Evanston Northwestern Hospital

Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Semi‑Automatic Defibrillator
Heart Save AED (ED300)
Digital Color Doppler Ultrasound System
MS22Plus
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: The researchers grew pancreatic tissue (above) so it incorporated a mesh-like electronic network (red). Cells within the tissue produce insulin (green). (Photo courtesy of Penn Medicine)

‘Cyborg’ Transplants Could Replace Pancreatic Tissue Damaged by Diabetes

Type 1 diabetes destroys insulin-producing islet cells, forcing patients to rely on lifelong insulin therapy or scarce organ transplants. Although lab-grown pancreatic tissue offers a promising alternative,... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.